Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTp) : a consensus statement from the TTp catalan group
Muñoz, Nadia Garcia (Hospital Universitari de Bellvitge)
Ortega, Sandra (Hospital Universitari de Bellvitge)
Solanich, Xavier (Hospital Universitari de Bellvitge)
Cid, Joan (Hospital Clínic i Provincial de Barcelona)
Díaz, Maribel (Hospital Clínic i Provincial de Barcelona)
Moreno, Ana B. (Hospital Clínic i Provincial de Barcelona)
Ancochea, Águeda (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Santos, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Hernández, Inés (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sanchez, Juan Manuel (Hospital Universitari Arnau de Vilanova)
Luaña, Armando (Hospital Universitari Arnau de Vilanova)
García, José (Universitat Rovira i Virgili)
Escoda, Lourdes (Universitat Rovira i Virgili)
Medina, Laura (Institut de Recerca Sant Pau)
Ferrer, Gonzalo José (Institut de Recerca Sant Pau)
López Pardo, Jordi (Institut de Recerca Sant Pau)
Céspedes, Roberto (Hospital Universitari de Girona Doctor Josep Trueta)
Díaz, Johana Alejandra (Hospital Universitari de Girona Doctor Josep Trueta)
Pons, Verónica (Hospital Universitari Vall d'Hebron)
Valcárcel, David (Vall d'Hebron Institut d'Oncologia)
Grifols, Joan Ramon (Universitat Autònoma de Barcelona. Banc de Sang i Teixits)
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	Thrombotic thrombocytopenic purpura (TTP) is a low prevalence disease characterized by severe deficiency of the enzyme ADAMTS13, leading to the development of thrombotic microangiopathy (TMA) and often resulting in severe organ disfunction. TTP is an extremely serious condition and, therefore, timely and appropriate treatment is critical to prevent life-threatening complications. Over the past 25 years, significant advances in the understanding of the pathophysiology of immune TTP have led to the development of readily available techniques for measuring ADAMTS13 levels, as well as new drugs that are particularly effective in the acute phase and in preventing relapses. These developments have improved the course of the disease. Given the complexity of the disease and its various clinical and laboratory manifestations, early diagnosis and treatment can be challenging. To address this challenge, a group of experienced professionals from the Catalan TTP group have developed this consensus statement to standardize terminology, diagnosis, treatment and follow up for immune TTP, based on currently available scientific evidence in the field. This guidance document aims to provide healthcare professionals with a comprehensive tool to make more accurate and timely diagnosis of TTP and improve patient outcomes.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Blood Transfusion, Vol. 22 Núm. 2 (march 2024) , p. 176-184, ISSN 2385-2070

DOI: 10.2450/BloodTransfus.522
PMID: 37677097

9 p, 535.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles